[8-K] SOBR Safe, Inc. Reports Material Event
Syndax Pharmaceuticals (SNDX) 鈥� Form 4 insider filing
Chief Financial Officer Keith A. Goldan acquired 1,226 common shares on 31-Jul-2025 under the company鈥檚 Employee Stock Purchase Plan (transaction code 鈥淛鈥�). The shares were purchased at $8.43 per share, representing an outlay of roughly $10.3 thousand. After the transaction, Goldan directly owns 93,676 SNDX shares.
No derivative positions were reported and no shares were sold. This is a routine, voluntary filing without indication of a broader corporate event; nevertheless, insider purchases can be interpreted as a sign of management confidence when funded with personal capital.
Syndax Pharmaceuticals (SNDX) 鈥� Comunicazione interna Form 4
Il Chief Financial Officer Keith A. Goldan ha acquisito 1.226 azioni ordinarie il 31 luglio 2025 nell'ambito del Piano di Acquisto Azioni per Dipendenti della societ脿 (codice transazione 鈥淛鈥�). Le azioni sono state acquistate a 8,43 $ ciascuna, per un investimento complessivo di circa 10,3 mila $. Dopo questa operazione, Goldan detiene direttamente 93.676 azioni SNDX.
Non sono state segnalate posizioni in strumenti derivati n茅 sono state vendute azioni. Si tratta di una comunicazione ordinaria e volontaria, senza indicazioni di eventi societari pi霉 ampi; tuttavia, gli acquisti da parte degli insider possono essere interpretati come un segnale di fiducia del management quando finanziati con capitale personale.
Syndax Pharmaceuticals (SNDX) 鈥� Presentaci贸n interna Formulario 4
El Director Financiero Keith A. Goldan adquiri贸 1,226 acciones ordinarias el 31 de julio de 2025 bajo el Plan de Compra de Acciones para Empleados de la compa帽铆a (c贸digo de transacci贸n 鈥淛鈥�). Las acciones fueron compradas a $8.43 por acci贸n, representando un desembolso aproximado de $10.3 mil. Tras la transacci贸n, Goldan posee directamente 93,676 acciones de SNDX.
No se reportaron posiciones en derivados ni se vendieron acciones. Esta es una presentaci贸n rutinaria y voluntaria sin indicios de un evento corporativo mayor; no obstante, las compras internas pueden interpretarse como una se帽al de confianza de la direcci贸n cuando se financian con capital personal.
Syndax Pharmaceuticals (SNDX) 鈥� 雮措秬鞛� Form 4 鞁犼碃
斓滉碃鞛毂呾瀯鞛�(Chief Financial Officer) Keith A. Goldan鞚� 2025雲� 7鞗� 31鞚� 須岇偓鞚� 歆侅洂 欤检嫕 甑Г 瓿勴殟(Employee Stock Purchase Plan)鞐� 霐半澕 1,226欤� 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟(瓯半灅 旖旊摐 鈥淛鈥�). 欤茧嫻 $8.43鞐� 欤检嫕鞚� 毵れ瀰頃橃棳 齑� 鞎� $10,300毳� 歆�於滍枅鞀惦媹雼�. 鞚� 瓯半灅 頉� Goldan鞚� 歆侅爲 93,676欤� SNDX 欤检嫕鞚� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�.
韺岇儩靸來拡 韽靺橃潃 氤搓碃霅橃 鞎婌晿鞙茧┌ 欤检嫕 毵る弰霃� 鞐嗢棃鞀惦媹雼�. 鞚措姅 雿� 韥� 旮办梾 鞚措菠韸鸽ゼ 雮橅儉雮挫 鞎婋姅 鞚检儊鞝侅澊瓿� 鞛愲皽鞝侅澑 鞁犼碃鞛呺媹雼�; 攴鸽熂鞐愲弰 攵堦惮頃橁碃 雮措秬鞛� 毵れ垬電� 臧滌澑 鞛愲掣鞙茧 鞚措（鞏挫鞚� 霑� 瓴届榿歆勳潣 鞁犽 鞁犿樃搿� 頃挫劃霅� 靾� 鞛堨姷雼堧嫟.
Syndax Pharmaceuticals (SNDX) 鈥� D茅claration d鈥檌niti茅 Formulaire 4
Le Directeur Financier Keith A. Goldan a acquis 1 226 actions ordinaires le 31 juillet 2025 dans le cadre du Plan d鈥橝chat d鈥橝ctions pour Employ茅s de la soci茅t茅 (code transaction 芦 J 禄). Les actions ont 茅t茅 achet茅es 脿 8,43 $ par action, repr茅sentant une d茅pense d鈥檈nviron 10,3 milliers de dollars. Apr猫s cette transaction, Goldan d茅tient directement 93 676 actions SNDX.
Aucune position sur d茅riv茅s n鈥檃 茅t茅 d茅clar茅e et aucune action n鈥檃 茅t茅 vendue. Il s鈥檃git d鈥檜ne d茅claration de routine et volontaire sans indication d鈥檜n 茅v茅nement corporatif plus large ; n茅anmoins, les achats d鈥檌niti茅s peuvent 锚tre interpr茅t茅s comme un signe de confiance de la direction lorsqu鈥檌ls sont financ茅s avec des fonds personnels.
Syndax Pharmaceuticals (SNDX) 鈥� Insider-Meldung Form 4
Chief Financial Officer Keith A. Goldan erwarb am 31. Juli 2025 1.226 Stammaktien im Rahmen des Mitarbeiter-Aktienkaufplans des Unternehmens (Transaktionscode 鈥濲鈥�). Die Aktien wurden zu einem Preis von 8,43 $ pro Aktie gekauft, was einem Aufwand von etwa 10,3 Tausend $ entspricht. Nach der Transaktion besitzt Goldan direkt 93.676 SNDX-Aktien.
Es wurden keine Derivatepositionen gemeldet und keine Aktien verkauft. Dies ist eine routinem盲脽ige, freiwillige Meldung ohne Hinweis auf ein gr枚脽eres Unternehmensereignis; dennoch k枚nnen Insider-K盲ufe als Zeichen des Vertrauens des Managements interpretiert werden, wenn sie mit eigenem Kapital finanziert werden.
- CFO increased personal ownership by 1,226 shares, adding to insider alignment and signaling incremental confidence.
- None.
Insights
TL;DR: Small ESPP purchase; neutral impact.
The CFO鈥檚 1,226-share buy adds less than 2% to his stake and under 0.2% of daily volume, so market impact should be minimal. Because the shares were acquired through the standing Employee Stock Purchase Plan rather than an open-market buy, the signal value is modest. Still, the absence of any sales keeps insider trading trends net positive.
TL;DR: Governance routine; no red flags.
ESPP participation is common for senior officers and aligns executive incentives with shareholders. The voluntary nature of the filing shows transparency, and no derivative leverage was added. Given the limited dollar size, the event is classified as non-impactful for governance risk assessments.
Syndax Pharmaceuticals (SNDX) 鈥� Comunicazione interna Form 4
Il Chief Financial Officer Keith A. Goldan ha acquisito 1.226 azioni ordinarie il 31 luglio 2025 nell'ambito del Piano di Acquisto Azioni per Dipendenti della societ脿 (codice transazione 鈥淛鈥�). Le azioni sono state acquistate a 8,43 $ ciascuna, per un investimento complessivo di circa 10,3 mila $. Dopo questa operazione, Goldan detiene direttamente 93.676 azioni SNDX.
Non sono state segnalate posizioni in strumenti derivati n茅 sono state vendute azioni. Si tratta di una comunicazione ordinaria e volontaria, senza indicazioni di eventi societari pi霉 ampi; tuttavia, gli acquisti da parte degli insider possono essere interpretati come un segnale di fiducia del management quando finanziati con capitale personale.
Syndax Pharmaceuticals (SNDX) 鈥� Presentaci贸n interna Formulario 4
El Director Financiero Keith A. Goldan adquiri贸 1,226 acciones ordinarias el 31 de julio de 2025 bajo el Plan de Compra de Acciones para Empleados de la compa帽铆a (c贸digo de transacci贸n 鈥淛鈥�). Las acciones fueron compradas a $8.43 por acci贸n, representando un desembolso aproximado de $10.3 mil. Tras la transacci贸n, Goldan posee directamente 93,676 acciones de SNDX.
No se reportaron posiciones en derivados ni se vendieron acciones. Esta es una presentaci贸n rutinaria y voluntaria sin indicios de un evento corporativo mayor; no obstante, las compras internas pueden interpretarse como una se帽al de confianza de la direcci贸n cuando se financian con capital personal.
Syndax Pharmaceuticals (SNDX) 鈥� 雮措秬鞛� Form 4 鞁犼碃
斓滉碃鞛毂呾瀯鞛�(Chief Financial Officer) Keith A. Goldan鞚� 2025雲� 7鞗� 31鞚� 須岇偓鞚� 歆侅洂 欤检嫕 甑Г 瓿勴殟(Employee Stock Purchase Plan)鞐� 霐半澕 1,226欤� 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟(瓯半灅 旖旊摐 鈥淛鈥�). 欤茧嫻 $8.43鞐� 欤检嫕鞚� 毵れ瀰頃橃棳 齑� 鞎� $10,300毳� 歆�於滍枅鞀惦媹雼�. 鞚� 瓯半灅 頉� Goldan鞚� 歆侅爲 93,676欤� SNDX 欤检嫕鞚� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�.
韺岇儩靸來拡 韽靺橃潃 氤搓碃霅橃 鞎婌晿鞙茧┌ 欤检嫕 毵る弰霃� 鞐嗢棃鞀惦媹雼�. 鞚措姅 雿� 韥� 旮办梾 鞚措菠韸鸽ゼ 雮橅儉雮挫 鞎婋姅 鞚检儊鞝侅澊瓿� 鞛愲皽鞝侅澑 鞁犼碃鞛呺媹雼�; 攴鸽熂鞐愲弰 攵堦惮頃橁碃 雮措秬鞛� 毵れ垬電� 臧滌澑 鞛愲掣鞙茧 鞚措（鞏挫鞚� 霑� 瓴届榿歆勳潣 鞁犽 鞁犿樃搿� 頃挫劃霅� 靾� 鞛堨姷雼堧嫟.
Syndax Pharmaceuticals (SNDX) 鈥� D茅claration d鈥檌niti茅 Formulaire 4
Le Directeur Financier Keith A. Goldan a acquis 1 226 actions ordinaires le 31 juillet 2025 dans le cadre du Plan d鈥橝chat d鈥橝ctions pour Employ茅s de la soci茅t茅 (code transaction 芦 J 禄). Les actions ont 茅t茅 achet茅es 脿 8,43 $ par action, repr茅sentant une d茅pense d鈥檈nviron 10,3 milliers de dollars. Apr猫s cette transaction, Goldan d茅tient directement 93 676 actions SNDX.
Aucune position sur d茅riv茅s n鈥檃 茅t茅 d茅clar茅e et aucune action n鈥檃 茅t茅 vendue. Il s鈥檃git d鈥檜ne d茅claration de routine et volontaire sans indication d鈥檜n 茅v茅nement corporatif plus large ; n茅anmoins, les achats d鈥檌niti茅s peuvent 锚tre interpr茅t茅s comme un signe de confiance de la direction lorsqu鈥檌ls sont financ茅s avec des fonds personnels.
Syndax Pharmaceuticals (SNDX) 鈥� Insider-Meldung Form 4
Chief Financial Officer Keith A. Goldan erwarb am 31. Juli 2025 1.226 Stammaktien im Rahmen des Mitarbeiter-Aktienkaufplans des Unternehmens (Transaktionscode 鈥濲鈥�). Die Aktien wurden zu einem Preis von 8,43 $ pro Aktie gekauft, was einem Aufwand von etwa 10,3 Tausend $ entspricht. Nach der Transaktion besitzt Goldan direkt 93.676 SNDX-Aktien.
Es wurden keine Derivatepositionen gemeldet und keine Aktien verkauft. Dies ist eine routinem盲脽ige, freiwillige Meldung ohne Hinweis auf ein gr枚脽eres Unternehmensereignis; dennoch k枚nnen Insider-K盲ufe als Zeichen des Vertrauens des Managements interpretiert werden, wenn sie mit eigenem Kapital finanziert werden.
FAQ
How many SNDX shares did the CFO buy?
At what price were the shares acquired?
What is the CFO's total direct ownership after the transaction?
Was this an open-market purchase?
Does this filing indicate any material corporate event?
